Ovarian Cancer Biomarkers: A Preliminary Study

• Research type

  Research Study

• Full title

  Preliminary Analysis of Candidate Biomarkers in Ovarian Tumours

• IRAS ID

  128710

• Contact name

  Jeremy Twigg

• Contact email

  jeremy.twigg@nhs.net;dawn.coverley@york.ac.uk

• Sponsor organisation

  South Tees NHS Foundation Trust

• Research summary

  Ovarian cancer is fatal. Survival depends on how early the disease is diagnosed. Currently there is only 1 biomarker, CA125, that is detectable in blood, which is used routinely in clinical practice to establish the likelihood of the disease being present. Often the level of this biomarker is normal in women when their ovarian cancer is confined to the ovaries.

  This aim of this study is to investigate whether CiZ1, a biomarker that has recently been shown to be raised in patients with asymptomatic early stage lung cancer, has the same potential to detect ovarian cancer in earlier stages of the disease process.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  13/SC/0283

• Date of REC Opinion

  25 Jun 2013

• REC opinion

  Further Information Favourable Opinion